NetScientific (LSE:NSCI) ROE % Adjusted to Book Value : -16.40% (As of Jun. 2023)

View and export this data going back to 2013. Start your Free Trial

What is NetScientific ROE % Adjusted to Book Value?

NetScientific's ROE % for the quarter that ended in Jun. 2023 was -12.30%. NetScientific's PB Ratio for the quarter that ended in Jun. 2023 was 0.75. NetScientific's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2023 was -16.40%.

NetScientific ROE % Adjusted to Book Value Historical Data

The historical data trend for NetScientific's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NetScientific ROE % Adjusted to Book Value Chart

NetScientific Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-144.33

-52.70

-25.63

-16.73

-19.12

NetScientific Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-14.86	-10.14	-17.51	-22.21	-16.40

Competitive Comparison of NetScientific's ROE % Adjusted to Book Value

For the Biotechnology subindustry, NetScientific's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NetScientific's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NetScientific's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where NetScientific's ROE % Adjusted to Book Value falls into.

NetScientific ROE % Adjusted to Book Value Calculation

NetScientific's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-13.96%	/	0.73
	=	-19.12%

NetScientific's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-12.30%	/	0.75
	=	-16.40%

NetScientific ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of NetScientific's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

NetScientific (LSE:NSCI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NetScientific PLC (LSE:NSCI) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 Saint Andrew Street, Holborn Circus, London, GBR, EC4A 3AG

Website

https://www.netscientific.net

NetScientific PLC is a transatlantic healthcare technology company. The group is focused on sourcing, funding and commercializing technologies and companies that have the potential to treat chronic disease and significantly improve the health and well-being of people. Its portfolio consists of WANDA Health, an analytics company that uses machine learning to derive a personalized risk score for Congestive Heart Failure patients, Glucosense a provider of a non-invasive glucose monitoring wearable device, Vortex Biosciences which is engaged in circulating tumor cell identification, selection and analysis for disease monitoring and personalized therapeutic prescribing, and Glycotest which provides non-invasive blood tests for liver cancers and fibrosis-cirrhosis.

NetScientific (LSE:NSCI) Headlines

No Headlines